** Materials for this course will be release on 06/24/2020 **

Cardiology Pharmacy Specialty Review Course for Recertification + RECERT EXAM Package (Cert # L209248)

Teaser: This online course will help you earn BCCP recertification credit. With this course, get comprehensive, practical guidance, with a variety of complex cases, including references for further study.

Tag: Certifications; Cardiology

ACPE Numbers: Various – see listing below  
Pre-Sale Date: 05/27/2020  
Content Release Date: 06/24/2020  
Expiration Date: 06/22/2021  
Activity Type: Application-based  
CE Credits: 25.25 (BPS and ACPE)  
Activity Fee: $475 (ASHP member); $675 (non-member)

Accreditation for Pharmacists  
The American College of Clinical Pharmacy (ACCP) and the American Society of Health-System Pharmacists (ASHP) are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Target Audience  
These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in cardiology pharmacy.

Activity Overview  
This course is intended for BCCPs in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS) to provide an overview of recent standards and guidelines that specialists should be familiar with in practice. The course uses a case-based approach to discuss patient care issues. In this series, faculty will:

- Review pertinent clinical topics and practice skills  
- List valuable resources for further self-study

This online course consists of 17 activities (see table below) and provides up to 25.25 hours of continuing pharmacy education credit and/or recertification credit.

Recertification Credit*  
Board certified pharmacists are eligible to receive up to 25.25 hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Copyright © 2020, American College of Clinical Pharmacy, Inc. and American Society of Health-System Pharmacists  
All rights reserved.
This course is not intended for those preparing to take the BPS Cardiology Pharmacy Specialty Examination for Certification. To prepare for the examination, please see courses here: [http://elearning.ashp.org/catalog/Cards-review](http://elearning.ashp.org/catalog/Cards-review)

These activities are part of the ACCP and ASHP professional development program for BCCP recertification approved by the BPS.

* Please note: Review Course for Recertification may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle.

<table>
<thead>
<tr>
<th>Learning Activity</th>
<th>ACPE Number</th>
<th>Credit Hours</th>
<th>*Assessment Pass Point</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Prevention of Cardiovascular Disease and Public Health</td>
<td>0217-9999-20-099-H01-P</td>
<td>1.50</td>
<td>TBD</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>0217-9999-20-100-H01-P</td>
<td>1.50</td>
<td></td>
</tr>
<tr>
<td>Blood Pressure Management in Adult Patients</td>
<td>0217-9999-20-102-H01-P</td>
<td>1.50</td>
<td></td>
</tr>
<tr>
<td><strong>Group 1 Assessment</strong></td>
<td></td>
<td><strong>4.50</strong></td>
<td></td>
</tr>
<tr>
<td>Stable Atherosclerotic Disease</td>
<td>0217-9999-20-103-H01-P</td>
<td>1.50</td>
<td>TBD</td>
</tr>
<tr>
<td>Anticoagulation</td>
<td>0217-9999-20-104-H01-P</td>
<td>1.50</td>
<td></td>
</tr>
<tr>
<td><strong>Group 2 Assessment</strong></td>
<td></td>
<td><strong>3.00</strong></td>
<td></td>
</tr>
<tr>
<td>Arrhythmias</td>
<td>0217-9999-20-105-H01-P</td>
<td>1.50</td>
<td>TBD</td>
</tr>
<tr>
<td>Drug Induced Cardiovascular Disease and Drugs to Avoid in Cardiovascular Disease</td>
<td>0217-9999-20-106-H01-P</td>
<td>1.50</td>
<td></td>
</tr>
<tr>
<td><strong>Group 3 Assessment</strong></td>
<td></td>
<td><strong>3.00</strong></td>
<td></td>
</tr>
<tr>
<td>Chronic Heart Failure</td>
<td>0217-9999-20-107-H01-P</td>
<td>1.50</td>
<td>TBD</td>
</tr>
<tr>
<td>Acute Decompensated Heart Failure</td>
<td>0217-9999-20-108-H01-P</td>
<td>1.50</td>
<td></td>
</tr>
<tr>
<td>Cardiac Transplantation and Mechanical Circulatory Support</td>
<td>0217-9999-20-109-H01-P</td>
<td>1.50</td>
<td></td>
</tr>
<tr>
<td><strong>Group 4 Assessment</strong></td>
<td></td>
<td><strong>4.50</strong></td>
<td></td>
</tr>
<tr>
<td>Acute Coronary Syndromes</td>
<td>0217-9999-20-110-H01-P</td>
<td>1.75</td>
<td>TBD</td>
</tr>
<tr>
<td>Cardiovascular Emergencies</td>
<td>0217-9999-20-111-H01-P</td>
<td>1.50</td>
<td></td>
</tr>
<tr>
<td><strong>Group 5 Assessment</strong></td>
<td></td>
<td><strong>3.25</strong></td>
<td></td>
</tr>
<tr>
<td>Pulmonary Arterial Hypertension</td>
<td>0217-9999-20-112-H01-P</td>
<td>1.25</td>
<td>TBD</td>
</tr>
<tr>
<td>Specialized Topics in Cardiovascular Disease</td>
<td>0217-9999-20-113-H01-P</td>
<td>1.25</td>
<td></td>
</tr>
<tr>
<td>Pharmacogenomics of Cardiovascular Disease</td>
<td>0217-9999-20-114-H01-P</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td><strong>Group 6 Assessment</strong></td>
<td></td>
<td><strong>3.50</strong></td>
<td></td>
</tr>
</tbody>
</table>
** Materials for this course will be release on 06/24/2020 **

<table>
<thead>
<tr>
<th>Course Title</th>
<th>ACPE Number</th>
<th>Credits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Principles of Information Management and Education Research Design, Biostatistics, and Literature Training and Education and Training</td>
<td>0217-9999-20-115-H04-P</td>
<td>2.00</td>
</tr>
<tr>
<td>Principles of Cardiology Pharmacy Practice Administration: Protocol Development and Quality Improvement, Pharmacoeconomics and Safe Medication Use</td>
<td>0217-9999-20-116-H04-P</td>
<td>1.50</td>
</tr>
<tr>
<td>Group 7 Assessment</td>
<td></td>
<td>3.50</td>
</tr>
</tbody>
</table>

**Learning Objectives**

After participating in this CPE activity, learners should be able to:

**Primary Prevention of Cardiovascular Disease and Public Health**
ACPE Number: 0217-9999-20-099-H01-P
- Identify the pharmacotherapeutic agents that reduce the risk of developing cardiovascular disease (CVD).
- Given a patient scenario, develop a treatment plan that incorporates lifestyle modifications and evidence-based pharmacotherapy to reduce the risk of an index cardiac event.
- Develop a tobacco cessation plan for a patient who requests assistance for a quit attempt.
- Describe the role of selecting appropriate statin potency for the primary prevention of CVD.
- Formulate discussion points that should be incorporated into a patient discussion regarding aspirin use for the primary prevention of CVD.
- Advise a patient on the most appropriate nonpharmacologic and pharmacotherapeutic options for managing obesity.

**Dyslipidemia**
ACPE Number: 0217-9999-20-100-H01-P
- Describe the role of cholesterol and lipoproteins in the development of atherosclerotic cardiovascular disease (ASCVD).
- Evaluate a patient’s ASCVD risk by appropriately using the 10-year ASCVD Risk Pooled Cohort Equations and optional risk markers.
- Establish goals of therapy, statin intensity and create a monitoring plan for patients receiving lipid-lowering therapies.
- Establish goals of therapy, select an appropriate statin intensity, and create a monitoring plan for patients receiving lipid-lowering therapies for primary and secondary prevention of ASCVD.
- Develop an appropriate treatment regimen for patients who are statin intolerant or unable to achieve goals of therapy on maximally tolerated statin therapy, according to the 2018 Guideline on the Management of Blood Cholesterol.
- Identify appropriate indications for the use of triglyceride-lowering therapies to manage hypertriglyceridemia.
- Evaluate the needs of special populations (e.g., those with diabetes, older adults, those with kidney disease), and adapt treatment strategies to optimize outcomes.
Blood Pressure Management in Adult Patients
ACPE Number: 0217-9999-20-102-H01-P

- Develop an optimal pharmacologic treatment plan for a patient with hypertension (HTN) according to practice guidelines and clinical trial evidence.
- Demonstrate appropriate drug selection and blood pressure goals for the treatment of HTN according to concomitant conditions and compelling indications.
- Devise an evidence-based treatment strategy for resistant HTN to achieve blood pressure goals.
- Construct appropriate drug therapy plans for the treatment of hypotension.

Stable Atherosclerotic Disease
ACPE Number: 0217-9999-20-103-H01-P

- Recommend patient-specific pharmacologic therapy for the management of stable ischemic heart disease (SIHD).
- Differentiate between the antianginal options for a patient with refractory angina.
- Develop an optimal pharmacologic regimen and monitoring plan for patients with peripheral arterial disease (PAD) considering individual patient symptomatology and characteristics.
- Develop an evidence-based pharmacologic regimen for secondary prevention of ischemic stroke and transient ischemic attack (TIA).
- Recommend risk factor modification strategies to prevent a recurrent event for patients with SIHD, PAD, and ischemic stroke/TIA.

Anticoagulation
ACPE Number: 0217-9999-20-104-H01-P

- Recommend a patient-specific pharmacotherapy plan to reduce the risk of stroke in patients with nonvalvular atrial fibrillation (NVAF).
- Devise an evidence-based pharmacotherapy plan for preventing and treating venous thromboembolism (VTE).
- Analyze the need for anticoagulant therapy in patients with atrial fibrillation or VTE.
- Determine appropriate reversal strategies for patients at risk of active bleeding, or actively bleeding while receiving anticoagulation therapy.
- Determine appropriate selection and dosing of anticoagulant therapy on the basis of patient-specific factors and drug interactions.
- Evaluate literature and clinical implications of data for patients receiving anticoagulant agents.

Arrhythmias
ACPE Number: 0217-9999-20-105-H01-P

- Describe the principles of basic electrocardiogram (ECG) interpretation.
- Compare and contrast risk factors for and etiologies, clinical features, signs and symptoms, and goals of therapy of sinus bradycardia, atrial fibrillation (AF), supraventricular tachycardia (SVT) (including Wolff-Parkinson-White [WPW] syndrome), premature ventricular complexes (PVCs), and ventricular tachycardia (VT).
- Compare and contrast appropriate pharmacologic and nonpharmacologic treatment options for sinus bradycardia, AF, SVT, PVCs, and VT.
- Compare and contrast the mechanisms of action of drugs used for ventricular rate control and conversion to and maintenance of sinus rhythm in patients with AF.
- Describe the risk of thromboembolism in patients with AF and the importance of anticoagulation in this population.
- Compare and contrast nonpharmacologic and pharmacologic methods of terminating and preventing recurrence of SVT.
**Materials for this course will be release on 06/24/2020**

- Compare and contrast nonpharmacologic and pharmacologic methods of terminating VT, preventing recurrence, and reducing the risk of sudden cardiac death
- Develop evidence-based patient-specific pharmacotherapy plans for patients with symptomatic sinus bradycardia, AF, SVT (including WPW), PVCs, and VT.
- Describe common and important drug-drug interactions associated with drugs used for the management of arrhythmias and their complications.

Drug Induced Cardiovascular Disease and Drugs to Avoid in Cardiovascular Disease
ACPE Number: 0217-9999-20-106-H01-P
- Identify potential drug-induced cardiovascular diseases.
- Analyze a medication list to determine causative agents for common drug-induced cardiovascular diseases.
- Evaluate potential medications that can contribute to the development of torsades de pointes.
- Review anticancer therapies that cause cardiovascular toxicities.
- Evaluate patient characteristics and laboratory values to assess the risk of heparin-induced thrombocytopenia and develop an appropriate treatment plan.

Chronic Heart Failure
ACPE Number: 0217-9999-20-107-H01-P
- Given a patient with heart failure (HF), describe the classifications, staging, clinical presentation, etiologies, and diagnostic considerations.
- Describe the pathophysiology of HF, focusing on the role that neurohormonal and other vasoactive agents play in HF progression.
- Given a patient with chronic HF, devise an appropriate pharmacologic and nonpharmacologic therapeutic plan, with an emphasis on guideline-directed therapy and management.
- Given a patient with chronic HF and several comorbidities, devise an appropriate evidence-based pharmacotherapy plan addressing specific comorbidities related to HF.

Acute Decompensated Heart Failure
ACPE Number: 0217-9999-20-108-H01-P
- Classify a patient with acute decompensated heart failure (ADHF) into a hemodynamic subset based on signs/symptoms, laboratory values, and hemodynamic measures obtained via pulmonary artery catheter (PAC) monitoring.
- Design an initial pharmacotherapeutic treatment and monitoring plan for a patient with ADHF based on hemodynamic subset.
- Devise a modified treatment and monitoring plan in a patient with ADHF and diuretic resistance.
- Compare and contrast the use of intravenous (IV) vasodilators and positive inotropes in the treatment of ADHF, and among the agents within each drug class.
- List strategies for reducing the risk of heart failure (HF) readmission among patients recovering from ADHF.
Cardiology Pharmacy Specialty Review
Course for Recertification

** Materials for this course will be release on 06/24/2020 **

Cardiac Transplantation and Mechanical Circulatory Support
ACPE Number: 0217-9999-20-109-H01-P
- Evaluate levels of risk in the cardiac transplant candidate.
- Derive rational peri- and postoperative rejection mitigation strategies in cardiac transplant recipients.
- Devise effective thromboprophylactic strategies for patients receiving percutaneous ventricular assist device support.
- Construct safe and effective drug therapy regimens for patients receiving extracorporeal membrane oxygenation support
- Design effective treatment plans for patients with complications of durable left ventricular assist device therapy.

Acute Coronary Syndromes
ACPE Number: 0217-9999-20-110-H01-P
- Distinguish between reperfusion strategies for acute coronary syndrome (ACS): ST- segment elevation myocardial infarction (STEMI) and non–ST-segment elevation (NSTEMI) ACS.
- Devise a pharmacotherapeutic treatment plan for a patient with STEMI undergoing primary percutaneous coronary intervention (PCI) and for a patient with NSTE-ACS undergoing an early invasive or ischemic-guided approach.
- Differentiate between the best possible pharmacologic options for preventing thrombotic events in the acute management of ACS.
- Analyze differences in evidence, pharmacology, pharmacokinetics, drug-drug interactions, monitoring, and adverse events between the P2Y12 inhibitors and anticoagulants used in ACS management.
- Devise an individualized evidence-based treatment plan for patients in need of secondary prevention post-ACS, including mortality-reducing therapies.

Cardiovascular Emergencies
ACPE Number: 0217-9999-20-111-H01-P
- Choose appropriate management pathways/treatment for a patient with cardiac arrest according to patient presentation.
- Differentiate between the various categories of shock.
- Select the optimal management strategies for the various types of shock.
- Construct a pharmacotherapy regimen for the various hypertensive crises.
- Select an appropriate management plan for a patient presenting with acute aortic syndrome.
- Design a pharmacotherapy plan for the management of acute ischemic stroke.

Pulmonary Arterial Hypertension
ACPE Number: 0217-9999-20-112-H01-P
- Describe the classification of pulmonary hypertension and implications for treatment.
- Discuss the importance of pulmonary arterial hypertension (PAH) pathobiology and the role of various pathways as treatment targets in the development of PAH-specific treatment.
- Define treatment goals for the management of PAH.
- Outline targeted medications for PAH, including indications, dosing, monitoring, and their place within current treatment algorithms.
- Identify common adverse effects and drug interactions associated with PAH medications.
- Highlight appropriate treatment approaches for the management of decompensated PAH.
- Design a treatment plan for a patient with PAH.
Specialized Topics in Cardiovascular Disease
ACPE Number: 0217-9999-20-113-H01-P

- Recommend empiric antibiotic therapy for patients with suspected infective endocarditis (IE).
- Develop a therapeutic plan regarding medication therapy for patients with IE or patients requiring prophylactic therapy for IE prevention.
- Identify patients who require IE prophylactic therapy.
- Develop a treatment plan for patients with pericarditis.
- Recommend appropriate therapy for patients with myocarditis.
- Plan a medication therapy regimen for patients with valvular heart disease.

Pharmacogenomics of Cardiovascular Disease
ACPE Number: 0217-9999-20-114-H01-P

- Apply Clinical Pharmacogenetics Implementation Consortium (CPIC) guidance in the clinical setting.
- Associate clinically actionable genetic polymorphisms with response to cardiovascular pharmacotherapies.
- For a given patient, estimate therapeutic response to antiplatelet therapy using CYP2C19 genotype information.
- For a given patient, analyze the impact of the SLCO1B1 genotype on the risk of myopathy with statins.
- For a given patient, estimate the dose of warfarin using VKORC1 and CYP2C9 genotype information.

Principles of Information Management and Education Research Design, Biostatistics, and Literature Training and Education and Training
ACPE Number: 0217-9999-20-115-H04-P

- Identify different types of data (nominal, ordinal, continuous) to determine the appropriate type of statistical test (parametric vs. nonparametric).
- Select appropriate statistical tests based on the sample distribution, data type, and study design.
- Identify the most appropriate study design to answer a given clinical question.
- Describe the key tenets of internal and external validity of cardiovascular-related trials.
- Describe the advantages and disadvantages of surrogate and composite outcomes in cardiovascular studies.

Principles of Cardiology Pharmacy Practice Administration: Protocol Development and Quality Improvement, Pharmacoeconomics and Safe Medication Use
ACPE Number: 0217-9999-20-116-H04-P

- Develop policies, procedures, and clinical protocols related to the medication use process.
- Identify formulary management activities to improve the prescribing of safe, effective, and affordable treatments in an organization.
- List high-risk medications and medication-related processes that are suited for a medication use evaluation (MUE) and be capable of managing the MUE process.
- Identify sources of quality measures relevant to your organization, and use quality and process improvement methods to achieve optimal outcomes.
- Describe proper documentation practices for clinical pharmacy services and identify the need for accurate documentation.
- Review pharmacoconomic principles and their application to patient care.
- Define a pharmacist's scope of practice and the importance of credentialing and privileging.
- Compare a medication error, adverse drug event (ADE), adverse drug reaction (ADR), and preventable ADE.
- Design an ADE reporting program, including committee structure, committee reporting mechanisms, and methods of detecting, reporting, and managing ADEs.
**Materials for this course will be released on 06/24/2020**

Faculty

William L. Baker, Pharm.D., FCCP, FACC, FAHA  
Associate Professor, Department of Pharmacy Practice  
University of Connecticut School of Pharmacy  
Storrs, Connecticut

Scott Bolesta, Pharm.D., FCCP, FCCM, BCPS  
Associate Professor, Department of Pharmacy Practice  
Nesbit School of Pharmacy, Wilkes University  
Wilkes-Barre, Pennsylvania

James C. Coons, Pharm.D., FCCP, BCCP  
Associate Professor, University of Pittsburgh School of Pharmacy  
Clinical Pharmacist, Cardiology, UPMC Presbyterian Hospital  
PGY2 Cardiology Residency Program Director  
Pittsburgh, Pennsylvania

Rhonda Cooper-DeHoff, Pharm.D., M.S., FCCP, FAHA, FACC  
Associate Professor and University Term Professor  
Department of Pharmacotherapy and Translation Research and Division of Cardiovascular Medicine  
Colleges of Pharmacy and Medicine  
Associate Director, Center for Pharmacogenomics  
University of Florida  
Gainesville, Florida

Paul P. Dobesh, Pharm.D., FCCP, BCPS, BCCP  
Professor of Pharmacy Practice  
University of Nebraska Medical Center College of Pharmacy  
Omaha, Nebraska

Steve Dunn, Pharm.D., FCCP, FAHA, BCPS, BCCP  
Pharmacy Clinical Coordinator, Heart and Vascular  
University of Virginia Health System  
Charlottesville, Virginia

Shannon Finks, Pharm.D., FCCP, FACC, BCPS, BCCP, AHSCP-CHC  
Professor, Department of Clinical Pharmacy  
University of Tennessee College of Pharmacy  
Memphis, Tennessee

Doug Jennings, Pharm.D., FCCP, FAHA, FACC, FHFSA, BCPS  
Clinical Pharmacy Manager, Heart Transplant  
New York Presbyterian Hospital  
Columbia University Irving Medical Center  
New York, New York
** Materials for this course will be release on 06/24/2020 **

Tracy E. Macaulay, Pharm.D., BCPS-AQ Cardiology, BCCP, AACC  
Associate Professor  
University of Kentucky College of Pharmacy  
Cardiology Clinical Pharmacy Specialist  
UK HealthCare  
Lexington, Kentucky

Zachary Noel, Pharm.D., BCPS, BCCP  
Assistant Professor, Department of Pharmacy Practice and Science  
University of Maryland School of Pharmacy

Carrie Oliphant, Pharm.D., FCCP, BCPS, BCCP, AACC  
Global Medical Information Specialist  
Med Communications, Inc.  
Memphis, Tennessee

Robert Page II, Pharm.D., MSPH, FCCP, FASHP, FAHA, FHFSA, BCPS-AQ Cardiology, BCGP  
Professor, Department of Clinical Pharmacy  
Professor, Department of Physical Medicine/Rehabilitation  
University of Colorado Skaggs  
School of Pharmacy and Pharmaceutical Sciences  
Aurora, Colorado

Mary Parker, Pharm.D., FCCP, FASHP, BCPS, BCCP  
Clinical Pharmacy Specialist-Ambulatory Care  
Durham VA Medical Center  
Durham, North Carolina

Brent Reed, Pharm.D., BCPS, BCCP  
Associate Professor of Pharmacy Practice and Science  
University of Maryland School of Pharmacy  
Baltimore, Maryland

Kelly C. Rogers, Pharm.D., FCCP, FACC, BCCP  
Professor, Department of Clinical Pharmacy and Translational Science  
University of Tennessee College of Pharmacy  
Memphis, Tennessee

Dustin Spencer, Pharm.D., MBA, BCPS, BCCP  
Clinical Director, Cardiopulmonary Diseases  
Cardinal Health  
Houston, Texas

Reviewers  
TBD
** Materials for this course will be release on 06/24/2020 **

Field Testers
TBD

Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP and ACCP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ASHP and ACCP education activities are qualified and selected by ASHP and ACCP and required to disclose any relevant financial relationships with commercial interests. ASHP and ACCP identifies and resolves conflicts of interest prior to an individual's participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

- Clinical Investigator: James C. Coons (United Therapeutics)
- Received Grant Funding/Research Support: James C. Coons (United Therapeutics), William L. Baker (Portola)
- Consultant/Member of Advisory Board: Paul P. Dobesh (Boehringer Ingelheim, Pfizer/BMS Alliance, Janssen Pharmaceuticals, Portola Pharmaceuticals), William L. Baker (Portola, Bayer), Steven P. Dunn (Abiomed, Inc.), Douglas L. Jennings (Abiomed, Inc., Janssen, Novartis)
- Nothing to Disclose: Scott Bolesta, Rhonda Cooper-DeHoff, Shannon W. Finks, Tracy E. Macaulay, Zachary R. Noel, Carrie S. Oliphant, Robert L. Page II, Mary H. Parker, Brent N. Reed, Kelly C. Rogers, Dustin D. Spencer
- Speaker's Bureau: Brandon E. Cave (Portola), Jerrica E. Shuster (Janssen)
- Other: Yee Ming Lee (Topic Editor Pharmacogenomics, Dynamed Plus)

All other planners, presenters, reviewers, ASHP and ACCP staff and others with an opportunity to control content report no financial relationships relevant to this activity.

Methods and CE Requirements
Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity.

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

System Technical Requirements
Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites.

View the minimum technical and system requirements for learning activities.

Development
These activities were developed by ACCP and ASHP.

To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for Board Certification Examinations.